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Objective The discriminative power of the Diabetic Neuropathy 
Symptom (DNS) and Diabetic Neuropathy Examination 
(DNE) score for diagnosing diabetic PNP, and their 
relation with cardiovascular Autonomic Function Testing 
(cAFT) and Electro Diagnostic Studies (EDS) are 
evaluated. 
Methods Three groups (matched for age and sex) were selected: 24 
diabetic patients with neuropathic foot ulcers (diabetes 
ulcus group), 24 diabetic patients without clinical 
neuropathy or ulcers (diabetes control group) and 21 
controls without diabetes (controls). In all participants the 
DNS- and DNE-score were assessed, and cAFT (Heart 
Rate Variability (HRV) and Baro Reflex Sensitivity 
(BRS)) and EDS were performed (Nerve Conduction 
Sum (NCS) score; muscle fiber conduction velocity: 
fastest/slowest ratio (F/S ratio)). 
Results Both the DNS and the DNE score discriminated between 
the diabetes ulcus and diabetes control group significantly 
(p<.001). The DNE score even discriminated between the 
diabetes control group and controls without diabetes 
(p<.05). Spearman's correlation coefficients between both 
DNS- and DNE-score and cAFT (HRV -.42 and -.44, 
respectively; BRS -.30 and -.29, respectively) and EDS 
(NCS .51 and .62, respectively; F/S ratio .44 and .62, 
respectively), were significant. Odds ratios were 
calculated for both DNS and DNE score with cAFT 
(HRV 4.4 and 5.7, respectively; BRS 20.7 and 14.2, 
respectively) and EDS (NCS 5.6 and 16.8, respectively; 
F/S ratio 7.2 and 18.8, respectively). 
Conclusions the DNS and DNE scores are capable to discriminate 
between patients with and without PNP, and are strongly 
related to cAFT and EDS. This further confirms the 
strength of the DNS and DNE scores in diagnosing 
diabetic PNP in daily clinical practice. 
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6.1 Introduction 
 
One of the major risk factors for the development of diabetic foot 
complications is distal symmetric sensorimotor polyneuropathy (PNP) 1,2. For 
diagnosing PNP, no gold standard is available. The San Antonio consensus 
panel has recommended that at least 1 measurement should be performed in 5 
different diagnostic categories 3. These are symptom scoring, physical 
examination scoring, Quantitative Sensory Testing (QST), cardiovascular 
Autonomic Function Testing (cAFT) and Electro-Diagnostic Studies (EDS). 
Because none of the existing symptom and physical examination scores for 
diabetic PNP completely fulfilled methodological criteria for diagnostic tests, 
the Diabetic Neuropathy Symptom (DNS) score and Diabetic Neuropathy 
Examination (DNE) score were developed 4,5. The construct validity of these 
scores was studied in relation to Semmes Weinstein monofilaments and 
Vibration Perception Threshold testing (both forms of QST), because of their 
known predictive value to the development of diabetic foot complications 6-9. 
cAFT has an important prognostic value for the prediction of diabetic foot 
complications 8, 10,11 and mortality due to cardiovascular problems 12,13. The 
prognostic value of EDS is less clear, although EDS is supposed to be the 
most sensitive diagnostic tool for diabetic PNP 14. The relation between the 
DNS- and DNE-scores and cAFT and EDS, respectively, has not yet been 
studied. 
The objective of this study is to assess the discriminative power of the DNS- 
and DNE-scores for diagnosing diabetic PNP, and their relation with cAFT 
and EDS, respectively. 
 
 
6.2 Patients and Methods 
 
Patients 
All participants were recruited from the Diabetes Outpatient Clinic 
(University Hospital Groningen) and from the Rehabilitation Centre 
Beatrixoord Haren, after informed consent. To study the discriminative 
power of the DNS- and DNE-score, three groups of subjects were studied. 
Selection was performed by checking the patient records. The first group 
consisted of 24 diabetic patients known with previous or present neuropathic 
foot ulcers (group DU). These ulcers were purely neuropathic by origin, as 
was confirmed by their localization (plantar surface of the foot at high 
pressure points), and by absence of peripheral arterial disease as described 
below. In the second group, 24 diabetic patients unknown with clinical 
neuropathy or foot ulcers (group DC) were included, this was confirmed by 
normal sensitivity to the 10 gram Semmes Weinstein Monofilament testing 
(performance as described previously) 5. The third group consisted of 21 
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control subjects with normal glucose tolerance (group C). All groups were 
matched for sex and age (within 5 yrs), and the diabetic groups for duration 
and type of diabetes (type 1/ type 2; type 1 DM was considered on clinical 
grounds when the onset of the disease was an ketoacidosis or before the age 
of 40 years) as well. Subjects with a history of or clinically apparent cardiac 
disease, electrocardiographic abnormalities or using betablockers or calcium 
antagonists were excluded. Peripheral arterial disease was excluded by 
normal ankle-arm indices (>0.90), toe-arm indices (>0.70) and normal 
plethysmography (crest time 0.22 sec) in all groups. Normal glucose 
tolerance of the control subjects was demonstrated by a fasting capillary 
blood glucose < 6.1 mmol/l and a blood glucose < 7.8 mmol/l 2h after a 75 gr 
oral glucose tolerance test. 
Details of the clinical characteristics of each group are given in Table 1.  
 
 
Table 1: Patient Characteristics 
 
 DU (n=24) DC (n=24) C (n= 21) 
mean age (years) 57.3 ± 11.4 52.2 ± 12.0 58.2 ± 9.9 
sex (M/F) 14/10 13/11 10/11 
mean duration of diabetes (years) 16.9 ± 12.0 13.1 ± 9.8  
type of diabetes (type 1/type 2) 5/19 8/16  
mean HbA1c (%) 8.3 ± 1.1 7.5 ± 0.8  
 
DU: diabetic patients with neuropathic ulcer; DC: diabetic patients without neuropathy; 




The DNS- and DNE-score (EB), cAFT (JL) and EDS (JH) were performed 
by different researchers, blinded for the group to which the participant was 
allocated. The researchers were acting independently and no information 
about the results was exchanged during the study. An overall neuropathy sum 
score, according to the San Antonio consensus, was composed. 
 
Diabetic Neuropathy Symptom (DNS) score 
Both the DNS-score and DNE-score have been described in detail elsewhere 
4,5. In short, the DNS score is a 4 item validated symptom score, with high 
predictive value to screen for PNP in DM 4. Symptoms of unsteadiness in 
walking, neuropathic pain, paraesthesia and numbness are elicited. The 
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presence of a symptom is scored as 1 point; the maximum score is 4 points. A 
score of one or higher is defined as positive for PNP. 
 
Diabetic Neuropathy Examination (DNE) score 
The DNE-score is a sensitive and validated hierarchical scoring system 5. The 
score contains 2 items concerning muscle strength, 1 concerning reflexes and 
5 concerning sensation, with a total of 8 items. Each item is scored from 0 to 
2 (0 is normal and 2 severely disturbed). The maximum score is 16 points. A 
score of more than 3 points is defined as positive for PNP. 
 
cardiovascular Autonomic Function Testing (cAFT) 
Cardiovascular autonomic function was assessed by analysis of heart rate 
variability (HRV) and baroreflex sensitivity (BRS). All participants were 
studied in the morning. All measurements took place in a quiet room with the 
temperature kept constant at 22oC. Blood pressure was monitored by a 
Finapres (Ohmeda 2300, Inglewood, Col., USA) and heart rate by an ECG 
monitor (Hewlett-Packard 78351T, Palo Alto, Ca., USA). After 30 min of 
supine rest, the Finapres and ECG signal were sampled at 100 Hz and stored 
on a personal computer during 15 min. Offline, 300 seconds of each 
recording was analyzed by the CARSPAN program (IEC ProGamma, 
Groningen, the Netherlands), as described previously 15,16. After artifact 
correction and stationarity check, discrete Fourier transformation of systolic 
blood pressure and RR interval length was performed. HRV analysis was 
performed in accordance with the guidelines of the Task Force of the 
European Society of Cardiology and the North American Society of Pacing 
and Electrophysiology 17. The total power frequency band (TP) of HRV was 
defined as 0.02-0.40 Hz. Because no reference values of HRV are available, 
the median of the control group was used, 9.2 ln(ms2). BRS was determined 
by the transfer function method and defined as the mean modulus between 
systolic blood pressure and heart rate variability in the 0.07-0.14 Hz 
frequency band with at least 0.5 coherence, expressed in ms/mmHg 15,16,18. A 
BRS lower than 3 ms/mmHg leads to high mortality rates in chronic heart 
failure and after myocardial infarction, in diabetes the prognostic value of the 
BRS is not yet known 19,20. In this study, a BRS < 3 ms/mmHg was 
considered as indicative for cardiovascular autonomic neuropathy. 
 
Electro-Diagnostic Studies (EDS) 
Nerve conduction studies were performed with standard surface stimulation 
and recording techniques using an electromyograph type Nicolet Viking IIe 
and IV with standard filter settings. All measurements were performed after 
warming in hot water (38°C) of fore arm and lower leg during at least 15 
minutes. Peak-peak amplitudes were used. Motor Nerve Conduction Velocity 
(MNCV) and amplitudes were measured in the left median (thenar) and 
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peroneal nerves (tibialis anterior). Sensory Nerve Conduction Velocities and 
amplitudes were measured antidromically with ring electrodes placed around 
the middle finger (median nerve) and stimulation lateral of the Achilles 
tendon (sural nerve). An overall Nerve Conduction Sum (NCS) score was 
defined as the number of these four nerves with an abnormal conduction 
velocity and amplitude, ranging from 0 (all normal) to 4 (all abnormal). 
Reference values from our own laboratory were used, see legend table 2. 
Invasive MFCV (I-MFCV) measurements were performed in the tibialis 
anterior muscle at rest by means of needle electrodes adapted from the 
method as described previously 21. In short, muscle fibers were stimulated in 
the distal part of the tibial anterior muscle directly by a small monopolar 
needle electrode (cathode) using a surface electrode as anode. Filter settings 
500 Hz-10 kHz, stimulation 0.2 ms, 1-2 mA. The resulting muscle fiber 
action potentials were detected at a known distance (50-60 mm) by a small 
concentric needle electrode. With this technique, action potentials supposed 
to represent individual muscle fibers were identified, and the resulting 
conduction velocities were calculated. As parameters the mean I-MFCV and 
the fastest/slowest ratio representing the scatter of conduction velocities were 
used and compared to normative values from our own laboratory. 
 
Neuropathy Sum score 
For this study, an overall score was composed of the 5 diagnostic categories 
of the San Antonio consensus: DNS-score (symptom score), DNE-score 
(examination score), BRS (cAFT) and NCS (EDS). Because SW-MF testing 
was used in patient selection, these data, representing QST as the fifth 
category of the San Antonio consensus 3, were also available. These 5 tests 
together formed the Neuropathy Sum score. For each abnormal test result 1 
point was given, the maximum score is 5 points. 
 
Statistics 
The statistical package SPSS-PC 10.0 was used to compute the descriptive 
statistics, ANOVA, Chi-Square tests, independent samples t-test, Spearman's 
correlation coefficient and Odds Ratio's. Unless otherwise indicated, mean 





Table 1 shows the patient characteristics. There were no significant 
differences between the groups for mean age (p= 0.15) and sex (p= 0.77) and 
for the DU and DC groups for the duration (p= 0.23) and type of diabetes 
(p=0.33). The mean HbA1c of the DC group was significantly lower 
(p<0.01) than of the DU group. 
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Results of DNS- and DNE-score for the 3 groups 
 
For the DNS-score, the scores (SD) of the DU, DC and C group are 2.29 
(1.23),  .44 (.84) and .38 (.74), respectively. Differences between DU and 
both DC and C, respectively, were significant, p<0.001 in both cases, but not 
between DC and C. 
For the DNE-score, the scores (SD) of the DU, DC and C groups are 8.90 
(1.98), 1.46 (2.02), and .43 (.81), respectively. Significant differences were 
found in all comparisons of the 3 groups, between DU and both DC and C 




Table 2: Results of the tests for PNP for the 3 groups 
 
 DU (n=24) 
DC 
(n=24) C (n= 21) 
DNS (% ≥ 1 points = abnormal)4 96% 26% 24% 
DNE (% > 3 points = abnormal)5 100% 13% 0% 
NCS (% ≥ 1 points = abnormal) 85% 32% 15% 
F/S ratio (% > 1.9 = abnormal) 91% 33% 10% 
BRS (% < 3 ms/mmHG)19,20 52% 0% 11% 
HRVtp (%< median) 95% 57% 50% 
Neuropathy Sum score (% ≥ 1 point) 100% 47% 40% 
 
DU: diabetic patients with neuropathic ulcer; DC: diabetic patients without neuropathy; 
C: controls. 
 
DNS  Diabetic Neuropathy Symptom score4 
DNE  Diabetic Neuropathy Examination score5 
NCS  Nerve Conduction Sum score (ref value own laboratory) 
F/S ratio Fastest/Slowest Ratio of Muscle Fiber Conduction Velocity 
(ref value own laboratory) 
BRS  Baro Reflex Sensitivity19,20 
HRVtp total power of Heart Rate Variability 
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Results of the PNP tests 
 
Table 2 shows the % of patients of the 3 groups who scored abnormal on the 
individual diagnostic tests and on the Neuropathy Sum score. The DNS- and 
DNE-score correctly identified the DU group in 96 and 100%, respectively, 
and the healthy controls in 76 and 100%, respectively. Almost a half (47%) 
of the patients of the DC group and 40% of the C group scored at least 1 
point on the Neuropathy Sum score, which means that they scored abnormal 
on at least 1 diagnostic category of the San Antonio consensus.  
Table 3 shows the specified results on the Neuropathy Sum score. 
 
 
Table 3: The results on the Neuropathy Sum (NS) score for the 3 groups. 
 
NS score 0 1 2 3 4 5 
DU (22)   1 12 6 3 
DC (23) 12 7 3 1   
C    (20) 12 6 2    
 





Relation of the DNS- and DNE-score with cAFT and EDS 
In Table 4 the relation of the DNS and DNE scores with cAFT (BRS and 
HRV) and EDS (NCS and I-MFCV) is shown. Furthermore, the Odds ratios 
are shown of these tests. 
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Table 4: Correlation (Spearmans' rho) and Odds Ratios (95% confidence 
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6.4 Discussion   
 
This study shows that the DNS- and DNE-score are capable to differentiate 
between subjects with and without neuropathy in diabetes. Previously, the 
construct validity of both scores already has been studied in relation to 
Semmes Weinstein Monofilaments and Vibration Perception Threshold 
testing 4,5, both Quantitative Sensory Tests known to be strong predictors of 
the development of diabetic foot complications. In this report, the DNS- and 
DNE-score are further validated with the Electro Diagnostic Studies (EDS) 
and cardiovascular Autonomic Function Testing (cAFT). There was a strong 
relation between the DNS- and DNE-score and EDS, both with nerve and 
muscle fiber conduction studies. Furthermore, the relation of the DNS- and 
DNE-score with cAFT was significant, although this was stronger for HRV 
than for BRS for both scores. These results further confirm the strength of the 
DNS- and DNE-score in diagnosing diabetic polyneuropathy. 
 
HRV and BRS are advanced measures, able to detect early abnormalities in 
cAFT 10-13. The relation of HRV with the parameters for PNP (DNS- and 
DNE-score, NCS, F/S ratio of MFCV) was stronger than for BRS. While 
HRV measures the efferent part of the baroreflex arc, i.e. vagal and 
sympathetic nerve-mediated modulation of heart rate, BRS measures the 
relation between input (blood pressure sensed at the carotid arteries and aorta 
baroreceptors) and the output (modulations of heart rate, myocardial 
contractility and peripheral arterial resistance) of the baroreflex. Thus, the 
differences in HRV and BRS in relation to diabetic PNP may be due to the 
fact that BRS assesses different aspects of cardiovascular reflex function than 
HRV. Interestingly, it has also been proposed that PNP and cAFT are distinct 
entities with a different pathogenesis 22, thereby explaining the previously 
noticed variable relation between cAFT and PNP.  
The Odds ratios for the DNS- and DNE-score, respectively, with NCS, 
MFCV (F/S ratio), HRV and BRS are high, which means that the DNS- and 
DNE-score are capable to predict the results of these other diagnostic tests. 
Performing the DNS- and DNE-score at the outpatient clinic gives a good 
clue about the necessity of performing these, more laborious, expensive and 
less patient friendly, laboratory tests. However, in our opinion, the necessity 
of complementary performance of cAFT and EDS next to the DNS- and 
DNE-score as proposed in the San Antonio consensus, is debatable in clinical 
practice. No specific therapeutic interventions are available for neuropathy 
besides strict diabetes regulation, symptomatic treatment of, for example, 
neuropathic pain, prevention and instruction. For screening, prevention and 
instruction, the performance of the DNS- and DNE-score, eventually in 
combination with QST, may be sufficient.  
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As expected, performance of these various tests for diabetic PNP shows large 
percentages of abnormality among the group of patients with neuropathic 
ulcers. Although the percentage with abnormal BRS is rather low compared 
with the percentages of the other tests, these patients are expected to have a 
very poor prognosis due to their high risk of cardiovascular complications 
19,20. In their treatment, hospitalisation and rehabilitation programme, this 
should be taken into account. Strikingly, 48% of this group with obvious 
neuropathy, has a BRS > 3 ms/mmHg. This supports the hypothesis that 
cAFT might develop differently from PNP, as an independent complication 
of diabetes. 
In both the diabetes group without neuropathy and the control group, 
abnormal tests results were found for most tests. This might be caused by 
lack of specificity of the tests, as shown in the control group, although it also 
shows that after careful and sensitive screening more abnormalities can be 
found, also in diabetic patients unknown with neuropathy, as expected after 
checking the records. The results of the DNS-score and the Neuropathy Sum 
score are most striking. In our previous DNS-score validation, we chose a 
cut-off value of ≥ 1 to define a sensitive measure for diabetic PNP. Our 
present values show that almost a quarter of our control group scores 
abnormal. The same problem will exist for other symptom scores, such as for 
example the NSS 14,23, because these scores do also score these four items of 
the DNS-score. The Neuropathy Sum score, based on the 5 diagnostic 
categories as advised by the San Antonio consensus 3, also shows high 
percentages of participants, even in the control group, with abnormal test 
results. Therefore, one should consider the risk of overdiagnosis by using all 
5 the diagnostic categories of the San Antonio consensus. Further research 
should be done to characterise an optimal set of diagnostic categories for 
diabetic PNP. 
 
In conclusion, this report shows that the DNS- and DNE-score allow to 
discriminate between patients with and without diabetic PNP. Both scores are 
strongly related to electrodiagnostic studies and cardiovascular autonomic 
function testing. These results, together with the previously published results 
of the validation of both scores, further confirm the strength of the DNS- and 
DNE-score in diagnosing diabetic polyneuropathy in clinical practice. 
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